Akebia Therapeutics (AKBA) Other Non Operating Income (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Other Non Operating Income of $3000.0 for Q1 2026, down 98.59% year-over-year from $213000.0 in Q1 2025, and down 94.83% quarter-over-quarter from $58000.0 in Q4 2025.
Akebia Therapeutics (AKBA) Other Non Operating Income (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Other Non Operating Income for 14 consecutive years, with $3000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 98.59% year-over-year to $3000.0; the TTM figure through Mar 2026 stood at $23000.0 (down 97.07% YoY), while the FY2025 annual figure was $58000.0, down 38.3% from the prior year.
- Other Non Operating Income eased to $3000.0 in Q1 2026 per AKBA's latest filing, from $58000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.2 million in Q3 2022 and bottomed at -$517000.0 in Q1 2024.
- Historically, Other Non Operating Income has averaged $257714.3 across 5 years, with a median of $30500.0 in 2025.
- Annual changes were most pronounced in 2022 — Other Non Operating Income jumped 604.35% — and 2024, when it plunged 290.0%.
- Akebia Therapeutics' Other Non Operating Income stood at $1.2 million in 2022, then slipped by 23.99% to $887000.0 in 2023, then sank by 31.12% to $611000.0 in 2024, then sank by 90.51% to $58000.0 in 2025, then sank by 94.83% to $3000.0 in 2026.
- Business Quant data shows AKBA's Other Non Operating Income at $3000.0 in Q1 2026, $58000.0 in Q4 2025, and -$10000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Akebia Therapeutics | 240.54 Mn | 84.99 Mn | 38.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | 58,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Jun 30, 2025 | -28,000.00 |
| Mar 31, 2025 | 213,000.00 |
| Dec 31, 2024 | 611,000.00 |
| Jun 30, 2024 | -39,000.00 |
| Mar 31, 2024 | -517,000.00 |
| Dec 31, 2023 | 887,000.00 |
| Sep 30, 2023 | -272,000.00 |
| Jun 30, 2023 | -10,000.00 |
| Sep 30, 2022 | 1.17 Mn |
| Jun 30, 2022 | 411,000.00 |
| Mar 31, 2022 | 1.13 Mn |
| Dec 31, 2021 | 560,000.00 |
| Sep 30, 2021 | 427,000.00 |
| Jun 30, 2021 | 1.27 Mn |
| Mar 31, 2021 | 161,000.00 |
| Dec 31, 2020 | -1.14 Mn |